trametinib

Trials studying trametinib

• phase2Pan Tumor Rollover Studyrecruitingn=1,500
• phase4Dabrafenib and/or Trametinib Rollover Studyrecruitingn=100
• phase2Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatmentsrecruitingn=40
• phase2TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancerrecruitingn=4,200
• phase4Pediatric Long-Term Follow-up and Rollover Studyrecruitingn=165
• phase224VA021; VATCH Trametinib for Ras/MAPK Pathway VAsactive not recruitingn=45
• phase3Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).completedn=870
• phase2Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanomaactive not recruitingn=16